Mindset Pharma Inc. and Emerging
Markets Consulting, LLC.
ORLANDO, FL -- March 24, 2022 -- InvestorsHub NewsWire -- via
Emerging
Markets -- In the world of emergent small cap companies there
are a few things we love to see. Chief among them are positive
shareholder letters from senior management.
And that's exactly what shareholders of Mindset
Pharma Inc. (Mindset) (CSE:
MSET) (FSE: 9DF) (OTCQB:
MSSTF), a drug discovery and development company
focused on creating next-generation psychedelic medicines to treat
neurological and psychiatric disorders, just got.
Here it is
but give us just a minute before you click over.
Shareholder letters can have a unique effect. Positive
shareholder letters are usually a window into a Company's
self-belief that there are positive developments and/or things are
otherwise going well and to share such developments with its
investors.
In the case of Mindset's recent offering we believe it's very
clear that CEO James Lanthier wants to hammer home two points as
indicated by its introductory titles.
Let's take a look at both points.
First, point one:
MSRD Partnership Validates Mindset's Psychedelic Drug
Development Approach and Provides Ongoing Funding
Lanthier is explicitly clear that this agreement is
transformative not just for Mindset, but also perhaps for the
psychedelic industry and eventually helping patients achieve
happier lives and better therapeutic outcomes using psychedelics.
MSRD is a member of the global Otsuka family of pharmaceutical
companies, a giant pharmaceutical company with massive capability
and influence. The fact that Mindset is inside their big tent
should not be overlooked. As Lanthier eloquently calls it, "a
bridge from traditional Big Pharma to the new emerging world of
psychedelic medicine."
Mindset is helping to build that bridge.
Development Platform Enables Multiple Clinical
Opportunities for a Variety of Modalities
Here's the line that is paramount for us:
"…we continue to evaluate and collect a strong critical data
package for our psilocybin-inspired Families 1 and 3 drug
candidates."
This may be the beginnings of what could be a drug pipeline for
Mindset. This is drug development so there are many, many rungs in
the ladder toward commercialization but what should be noted here
is that the there is a stated intention to create a portfolio of
therapeutics. More products can equal more commercialization and
more potential revenue.
Mindset's letter suggests that the Company is in a very good
place and that it wants to make sure that its shareholders know
it.
About The Emerging Markets Report:
The Emerging Markets Report is owned and operated
by Emerging Markets Consulting (EMC), a syndicate of investor
relations consultants representing years of experience. Our network
consists of stockbrokers, investment bankers, fund managers, and
institutions that actively seek opportunities in the micro and
small-cap equity markets.
For more informative reports such as this, please sign up
at https://emergingmarketsconsulting.com/
Must Read OTC Markets/SEC policy on stock promotion and
investor protection
Section 17(b) of the Securities Act of 1933 requires that any
person that uses the mails to publish, give publicity to, or
circulate any publication or communication that describes a
security in return for consideration received or to be received
directly or indirectly from an issuer, underwriter, or dealer, must
fully disclose the type of consideration (i.e. cash, free trading
stock, restricted stock, stock options, stock warrants) and the
specific amount of the consideration. In connection therewith, EMC
has received the following compensation and/or has an agreement to
receive in the future certain compensation, as described below.
EMC has been paid $250,000 by Mindset Pharma, Inc. for various
marketing services including this report. EMC does not
independently verify any of the content linked-to from this
editorial. https://emergingmarketsconsulting.com/disclaimer/
Emerging Markets Consulting, LLC
Florida Office
390 North Orange Ave STE 2300
Orlando, FL 32801
E-mail: jamespainter@emergingmarketsllc.com
Web: https://emergingmarketsconsulting.com/
SOURCE: Emerging
Markets
Mindset Pharma (CSE:MSET)
Historical Stock Chart
From Oct 2024 to Nov 2024
Mindset Pharma (CSE:MSET)
Historical Stock Chart
From Nov 2023 to Nov 2024